260 related articles for article (PubMed ID: 18997048)
1. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer.
Komar G; Seppänen M; Eskola O; Lindholm P; Grönroos TJ; Forsback S; Sipilä H; Evans SM; Solin O; Minn H
J Nucl Med; 2008 Dec; 49(12):1944-51. PubMed ID: 18997048
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5.
Ziemer LS; Evans SM; Kachur AV; Shuman AL; Cardi CA; Jenkins WT; Karp JS; Alavi A; Dolbier WR; Koch CJ
Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):259-66. PubMed ID: 12552344
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of tumour blood flow, [¹⁸F]EF5 and [¹⁸F]FDG PET/CT imaging in patients with head and neck cancer treated with radiochemotherapy.
Komar G; Lehtiö K; Seppänen M; Eskola O; Levola H; Lindholm P; Sipilä H; Seppälä J; Grénman R; Solin O; Minn H
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2042-50. PubMed ID: 24898846
[TBL] [Abstract][Full Text] [Related]
4. Repeatability of tumour hypoxia imaging using [
Silvoniemi A; Suilamo S; Laitinen T; Forsback S; Löyttyniemi E; Vaittinen S; Saunavaara V; Solin O; Grönroos TJ; Minn H
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):161-169. PubMed ID: 29075831
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models.
Chitneni SK; Bida GT; Zalutsky MR; Dewhirst MW
J Nucl Med; 2014 Jul; 55(7):1192-7. PubMed ID: 24854792
[TBL] [Abstract][Full Text] [Related]
6. 18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model.
Chitneni SK; Bida GT; Yuan H; Palmer GM; Hay MP; Melcher T; Wilson WR; Zalutsky MR; Dewhirst MW
J Nucl Med; 2013 Aug; 54(8):1339-46. PubMed ID: 23740105
[TBL] [Abstract][Full Text] [Related]
7. Radiation dosimetry and biodistribution of the hypoxia tracer (18)F-EF5 in oncologic patients.
Lin LL; Silvoniemi A; Stubbs JB; Rengan R; Suilamo S; Solin O; Divgi C; Eskola O; Sorger JM; Stabin MG; Kachur A; Hahn SM; Grönroos TJ; Forsback S; Evans SM; Koch CJ; Minn H
Cancer Biother Radiopharm; 2012 Sep; 27(7):412-9. PubMed ID: 22897720
[TBL] [Abstract][Full Text] [Related]
8. Detection of hypoxia by [18F]EF5 in atherosclerotic plaques in mice.
Silvola JM; Saraste A; Forsback S; Laine VJ; Saukko P; Heinonen SE; Ylä-Herttuala S; Roivainen A; Knuuti J
Arterioscler Thromb Vasc Biol; 2011 May; 31(5):1011-5. PubMed ID: 21372297
[TBL] [Abstract][Full Text] [Related]
9.
Qian Y; Von Eyben R; Liu Y; Chin FT; Miao Z; Apte S; Carter JN; Binkley MS; Pollom EL; Harris JP; Prionas ND; Kissel M; Simmons A; Diehn M; Shultz DB; Brown JM; Maxim PG; Koong AC; Graves EE; Loo BW
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1183-1192. PubMed ID: 29859786
[TBL] [Abstract][Full Text] [Related]
10. Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study.
Souvatzoglou M; Grosu AL; Röper B; Krause BJ; Beck R; Reischl G; Picchio M; Machulla HJ; Wester HJ; Piert M
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1566-75. PubMed ID: 17447061
[TBL] [Abstract][Full Text] [Related]
11. Imaging of blood flow and hypoxia in head and neck cancer: initial evaluation with [(15)O]H(2)O and [(18)F]fluoroerythronitroimidazole PET.
Lehtiö K; Oikonen V; Grönroos T; Eskola O; Kalliokoski K; Bergman J; Solin O; Grénman R; Nuutila P; Minn H
J Nucl Med; 2001 Nov; 42(11):1643-52. PubMed ID: 11696633
[TBL] [Abstract][Full Text] [Related]
12. Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma.
Koch CJ; Scheuermann JS; Divgi C; Judy KD; Kachur AV; Freifelder R; Reddin JS; Karp J; Stubbs JB; Hahn SM; Driesbaugh J; Smith D; Prendergast S; Evans SM
Eur J Nucl Med Mol Imaging; 2010 Nov; 37(11):2048-59. PubMed ID: 20585774
[TBL] [Abstract][Full Text] [Related]
13. 18F-EF5 PET Is Predictive of Response to Fractionated Radiotherapy in Preclinical Tumor Models.
Ali R; Apte S; Vilalta M; Subbarayan M; Miao Z; Chin FT; Graves EE
PLoS One; 2015; 10(10):e0139425. PubMed ID: 26431331
[TBL] [Abstract][Full Text] [Related]
14. Tracer level electrophilic synthesis and pharmacokinetics of the hypoxia tracer [(18)F]EF5.
Eskola O; Grönroos TJ; Forsback S; Tuomela J; Komar G; Bergman J; Härkönen P; Haaparanta M; Minn H; Solin O
Mol Imaging Biol; 2012 Apr; 14(2):205-12. PubMed ID: 21448777
[TBL] [Abstract][Full Text] [Related]
15. ¹⁸F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with ¹⁸F-FMISO.
Chen L; Zhang Z; Kolb HC; Walsh JC; Zhang J; Guan Y
Nucl Med Commun; 2012 Oct; 33(10):1096-102. PubMed ID: 22836736
[TBL] [Abstract][Full Text] [Related]
16. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N
J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456
[TBL] [Abstract][Full Text] [Related]
17. Imaging of Tumor Hypoxia With 18F-EF5 PET/MRI in Cervical Cancer.
Narva SI; Seppänen MP; Raiko JRH; Forsback SJ; Orte KJ; Virtanen JM; Hynninen J; Hietanen S
Clin Nucl Med; 2021 Dec; 46(12):952-957. PubMed ID: 34619699
[TBL] [Abstract][Full Text] [Related]
18. [18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure.
Dolbier WR; Li AR; Koch CJ; Shiue CY; Kachur AV
Appl Radiat Isot; 2001 Jan; 54(1):73-80. PubMed ID: 11144255
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles.
Koch CJ; Hahn SM; Rockwell K; Covey JM; McKenna WG; Evans SM
Cancer Chemother Pharmacol; 2001 Sep; 48(3):177-87. PubMed ID: 11592338
[TBL] [Abstract][Full Text] [Related]
20. A simplified synthesis of the hypoxia imaging agent 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[(18)F]pentafluoropropyl)-acetamide ([18F]EF5).
Chitneni SK; Bida GT; Dewhirst MW; Zalutsky MR
Nucl Med Biol; 2012 Oct; 39(7):1012-8. PubMed ID: 22727821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
